Upcoming Milestones
The Company has set forth the following for pipeline progression:
NTLA-2001 for ATTR amyloidosis:
Report additional interim data from Phase 1 study on February 28
Initiate Part 2, a single-dose expansion cohort, of the Phase 1 study of NTLA-2001 in Q1 2022
Complete enrollment of Phase 1 study for both ATTRv-PN and ATTR-CM subjects in 2022
NTLA-2002 for HAE: Present interim data from Phase 1/2 study in 2H 2022
NTLA-3001 for AATD: Plan to file an IND or IND-equivalent in 2023
NTLA-5001 for AML: Continue to enroll patients in Phase 1/2a study in 2022
NTLA-6001 for CD30+ Lymphomas: Plan to present preclinical data at an upcoming scientific conference in 2022
Pipeline Expansion:
Advance at least one new in vivo development candidate by the end of 2022
Advance additional novel platform capabilities in 2022
- https://finance.yahoo.com/news/intellia-therapeutics-announces-fourth-quarter-123000678.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.